share_log

Disc Medicine Announces Exclusive Licensing Agreement With Mabwell Therapeutics For Novel Anti-TMPRSS6 Monoclonal Antibodies To Modulate Iron Homeostasis; Mabwell To Receive $10M Upfront Payment And Up To $412.5M In Milestones

Benzinga Real-time News ·  Jan 20, 2023 07:02
Disc Medicine Announces Exclusive Licensing Agreement With Mabwell Therapeutics For Novel Anti-TMPRSS6 Monoclonal Antibodies To Modulate Iron Homeostasis; Mabwell To Receive $10M Upfront Payment And Up To $412.5M In Milestones
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment